Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters.
The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor with a Bmax > or = 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R < or = 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study.
Bolla
M
M
Department of Radiotherapy, C.H.U.A. Michallon, Grenoble, France.
Chedin
M
M
Colonna
M
M
Marron-Charrière
J
J
Rostaing-Puissant
B
B
Pasquier
D
D
Panh
M H
MH
Winckel
P
P
Chambaz
E M
EM
D000704:Analysis of Variance; D001943:Breast Neoplasms / Q000378:metabolism* / Q000628:therapy; D002277:Carcinoma / Q000378:metabolism* / Q000628:therapy; D003131:Combined Modality Therapy; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
D004815:Epidermal Growth Factor; D066246:ErbB Receptors